Terns Pharmaceuticals Inc at JMP Securities Hematology Oncology Summit (Virtual) Transcript
Welcome to our annual JMP hematology and oncology conference. My name is Silven Tuerkcan. I'm a senior analyst at JMP Citizens. I cover precision medicines here. And if you would like to ask any question during today's call, please submit them via chat or you can e-mail me directly. Right now, it's my pleasure to host Erin Quirk, Head of R&D at Terns Pharmaceuticals. And in the background, we'll have Mark Vignola, CFO of Terns as well. Thank you so much. Thank you for joining us today.
Thank you, Silven. It's our pleasure. We really appreciate the invitation.
Great. Thank you. So, to start off, I know you have a company and you span several indications here, but I would like to focus on your oncology programs today. Could you please talk about the BCR-ABL inhibitor landscape in CML and how your third generation TKI would fit into the existing space?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |